The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | CLL17 trial: fixed-duration vs continuous targeted treatment for previously untreated CLL
In this press briefing, Othman Al-Sawaf, MD, PhD, University Hospital of Cologne, Cologne, Germany, shares results from the Phase III CLL17 trial (NCT04608318) comparing fixed-duration versus continuous targeted treatment for patients with previously untreated chronic lymphocytic leukemia (CLL). This press briefing took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
